Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial

Hepatology ◽  
2021 ◽  
Author(s):  
Lai Wei ◽  
Tingting Zhao ◽  
Ji Zhang ◽  
Qing Mao ◽  
Guozhong Gong ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Randomized Clinical Trial ◽  
Chronic Hepatitis B ◽  
Therapeutic Vaccine ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of YinQiSanHuang-antiviral decoction on chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial

2020 ◽  
Author(s):  
qing-juan wu ◽  
Wen-Liang Lv ◽  
Juan-Mei Li ◽  
Ting-Ting Zhang ◽  
Wen-hui Zhou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Hepatitis ◽  
Placebo Group ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Efficacy And Safety ◽  
Double Blinded ◽  
Blinded Trial

Abstract Background: Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better clinical efficacy than conventional antiviral for treatment of CHB. YinQiSanHuang-antiviral decoction (YQSH) is a TCM compound preparation used for over thirty years, and has shown its effect on anti-hepatitis B virus and slowing progression of hepatitis B-related liver diseases in a small-scale clinical observation. Until now there is no convincing evidence demonstrating the clinical effectiveness of YQSH in anti-liver cirrhosis and anti-liver cancer. To evaluate the efficacy and safety of YQSH and its preventive effect on hepatitis B cirrhosis, a rigorously designed randomized, double-blind, placebo-controlled clinical trial is needed. Methods: This is a multicenter, randomized, placebo-controlled, double-blinded trial, 5 hospitals involved in. Totally 802 patients are randomly allocated to two groups: the YQSH group (n=401) or the placebo group (n=401). The YQSH group receives YQSH with Entecavir, the placebo group receives granule of placebo with Entecavir. Patients receive treatment for 52 weeks, and then are followed up for 52±2 weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are HBV-DNA negative rate, HBsAg negative rate, HBeAg seroconversion rate, liver function (Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), serum albumin (ALB) and total bilirubin (TBIL)), spleen thickness, evaluation scores of patients’ clinical symptoms and safety assessment. Outcomes will be assessed at baseline and after treatment. Discussion: Combination therapy could become a trendy of treatment of CHB, this trial expecting to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB. Trial registration: ChiCTR1900021521, this protocol was registered in the Chinese Clinical Trial Registry (URL: http://www.chictr.org.cn) on February 25th, 2019. Keywords: chronic hepatitis B, cirrhosis, traditional Chinese medicine, clinical trial, efficacy

scholarly journals Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)

PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0201236 ◽  
Author(s):  
Mamun Al Mahtab ◽  
Sheikh Mohammad Fazle Akbar ◽  
Julio Cesar Aguilar ◽  
Gerardo Guillen ◽  
Euduaro Penton ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Therapeutic Vaccine ◽  
Phase Iii ◽  
Phase Iii Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document